

ANNEXURE - 1

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition


Name of the Target Company (TC)	ERIS Lifesciences Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	1. UTI Mutual Fund - Acquirer 2. Shinsei UTI India Fund (Class A) - PAC 3. UTI India Dynamic Equity Fund – PAC 4. EMIRATES ISLAMIC INDIA EQUITY FUND – PAC 5. JSS RESPONSIBLE EQUITY INDIA – PAC 6. K B INDIA GROWTH EQUITY FUND – PAC 7. UNITED CHINA INDIA DYNAMIC GROWTH FUND – PAC 8. UTI INDIA BALANCE FUND -PAC		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE, NSE		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	67,15,984	4.9462	4.9462
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	67,15,984	4.9462	4.9462
Details of acquisition			
a) Shares carrying voting rights acquired	1,52,258	0.1121	0.1121
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each			

category) acquired			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
e) Total (a+b+c+/-d)	1,52,258	0.1121	0.1121
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	68,68,242	5.0583	5.0583
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
e) Total (a+b+c+d)	68,68,242	5.0583	5.0583
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/ encumbrance, etc.)	Secondary Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not applicable		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	May 19, 2021		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 13.58 Crores		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 13.58 Crores		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 13.58 Crores		

Part-B***

Name of the Target Company: ERIS Lifesciences Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
UTI MUTUAL FUND	NO	
Shinsei UTI India Fund (Class A)	NO	
UTI India Dynamic Equity Fund	NO	
EMIRATES ISLAMIC INDIA EQUITY FUND	NO	
JSS RESPONSIBLE EQUITY INDIA	NO	
K B INDIA GROWTH EQUITY FUND	NO	
UNITED CHINA INDIA DYNAMIC GROWTH FUND	NO	
UTI INDIA BALANCE FUND	NO	



Signature of the acquirer / Authorised Signatory

Place: Mumbai

Date: 20.05.2021

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.